Figure 2

Time to discontinuation of first and subsequent anti-TNF therapy. When discontinuation was defined as: (a) a gap in therapy of more than 60 days or starting a non-index biologic agent, the median time to discontinuation was 12.5 months for first-line therapy and 9.7 months for subsequent-line therapy (p < 0.001); or (b) a gap in therapy of more than 180 days or starting a non-index biologic agent, the median time to discontinuation was 15.6 months for first-line therapy and 12.3 months for subsequent-line therapy (p < 0.001).